LQDA shareholders who lost money after a court found that Yutrepia infringed two valid United Therapeutics patent claims may have the right to seek recovery. The investigation includes Liquidia’s forecast of more than $1 billion in 2027 net revenue.

NEW YORK, Oct. 5, 2026 /PRNewswire/ — Liquidia Corporation (NASDAQ: LQDA), whose CEO pointed investors toward more than $1 billion in 2027 net revenue, saw its shares fall roughly 57% after a court found that Yutrepia infringed two valid claims of United Therapeutics’ ‘327 patent. If you lost money on LQDA, you may have the right to seek recovery whether or not you still hold the shares. Shareholders who suffered losses are encouraged to check their eligibility to recover losses now or to contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

The $1 billion target was stated on Liquidia’s August 12, 2026 earnings call, where CEO Roger Jeffs said: “These results give us confidence that we’re well on our way to more than $1 billion in net revenue in 2027.” Yutrepia sales totaled $300.3 million for the first six months of 2026, according to the Company’s Q2 2026 Form 10-Q. The litigation discussion on that call did not expressly connect the ‘327 patent case to the $1 billion forecast. It also did not quantify how an adverse ruling could affect that forecast.

The court found two of the six asserted ‘327 patent claims valid and infringed. The ruling raised the risk of remedies including removal of Yutrepia’s PH-ILD indication and broader limits on product availability. United Therapeutics has also sought an injunction. Levi & Korsinsky is investigating potential securities law violations on behalf of LQDA shareholders, and there is no upfront cost to have your losses evaluated.

Lost money on Liquidia? Submit your LQDA loss details today or call Joseph E. Levi, Esq. at (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the LQDA Investigation

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Liquidia Corporation made materially false or misleading statements regarding the ‘327 patent litigation over Yutrepia and the Company’s outlook for more than $1 billion in net revenue in 2027. When a court found that Yutrepia infringed two valid claims of United Therapeutics’ ‘327 patent, the stock price declined sharply.

Q: When did Liquidia Corporation allegedly mislead investors?A: The investigation concerns statements made before the court’s ‘327 patent ruling became public. These statements allegedly caused investors to purchase LQDA securities at inflated prices.

Q: What do LQDA investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my LQDA shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought LQDA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/liquidia-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-liquidia-lqda-302898825.html

SOURCE Levi & Korsinsky, LLP